Drug intelligence / Profile preview

Celularity Placental Matrix

Development stage: Preclinical
Lead developer: Celularity
Modality: Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems, Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

Celularity Placental Matrix (CPM) is a placental-derived biomaterial medical device developed by Celularity in collaboration with Arthrex. Designed for soft tissue management, CPM serves as a structural scaffold that facilitates the body's natural healing and regenerative processes. The product is currently in the preclinical stage of development, with Celularity intending to pursue regulatory clearance via the FDA's 510(k) pathway. As a biomaterial, it leverages the inherent properties of the placental extracellular matrix to provide a microenvironment suitable for tissue repair.

Other names: Celularity Placental MatrixCPM

Beyond the preview

Go deeper on Celularity Placental Matrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celularity Placental Matrix.

Explore the full profile